- Home
- JANX
as 06-20-2025 4:00pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $94.29 | AVG Volume (30 days): | 808.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.48 - $71.71 | Next Earning Date: | 08-06-2025 |
| Revenue: | $9,336,000 | Revenue Growth: | 28.12% |
| Revenue Growth (this year): | -95.72% | Revenue Growth (next year): | 1470.82% |
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | JANX | Chief Business Officer | May 1 '25 | Sell | $32.28 | 3,333 | $106,744.55 | 82,539 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Apr 21 '25 | Sell | $30.00 | 3,334 | $100,020.00 | 82,539 |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
Business Wire
a month ago
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Clinical Trials Arena
a month ago
Janux commences Phase Ib studies in trial for prostate cancer treatment
Insider Monkey
2 months ago
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential
Business Wire
2 months ago
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
Insider Monkey
2 months ago
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
Insider Monkey
3 months ago
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?
Insider Monkey
3 months ago
Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.